Application of nanomedicine in cardiovascular diseases and stroke

Current Pharmaceutical Design

Volumn 17, Issue 18, 2011, Pages 1825-1833

  Kim, Kye S ^a   Khang, Gilson ^b   Lee, Dongwon ^a  

^a Chonbuk National University   (South Korea)

^b Sutter Medical Center   (United States)

Author keywords

Cardiovascular diseases; Drug delivery; Imaging; Nanomaterials

Indexed keywords

ALBUMIN; ASPARAGINASE MACROGOL; CELL ADHESION MOLECULE; DENDRIMER; DOXORUBICIN; EPITOPE; FERUCARBOTRAN; GOLD; IRON OXIDE; LIPID; LIPOSOME; NANOMATERIAL; NANOSHELL; PACLITAXEL; POLYMER; REACTIVE OXYGEN METABOLITE; SUPERPARAMAGNETIC IRON OXIDE; VIVAGEL;

ABDOMINAL PAIN; ANEMIA; APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL DEATH; CLINICAL PRACTICE; CLINICAL TRIAL; CYTOPENIA; EXTRACELLULAR MATRIX; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOPENIA; MACROPHAGE; MICELLE; NANOMEDICINE; NANOTECHNOLOGY; NEUTROPENIA; OXIDATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RASH; REVIEW; SENSORY NEUROPATHY; STROKE; THROMBUS; URTICARIA;

CARDIOVASCULAR DISEASES; HUMANS; NANOMEDICINE; NANOSTRUCTURES; STROKE;

EID: 79960339572     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211796390967     Document Type: Review

References (87)

1. Feynman RP. There's plenty of room at the bottom. Annual meeting of American Physiological Society. 1959 Dec 29; California Institute of Technology, Pasadena, CA,
2. Heinze T. Nanoscience and Nanotechnology in Europe: Analysis of Publications and Patent Applications including Comparisons with the United States. Nanotechnology Law and Business 2004; 1: 1-19.
3. Nanotechnology: A report of the U.S. Food and Drug Administration Nanotechnology Task Force 2007.
4. McCarthy JR. Nanomedicine and Cardiovascular Disease. Curr Cardiovasc Imaging Rep 2010; 3: 42-49.
5. Choi HS, Ipe BI, Misra P, Lee JH, Bawendi MG, Frangioni JV. Tissue- and organ-selective biodistribution of NIR fluorescent quantum dots. Nano Lett 2009; 9: 2354-2359.
6. Perelshtein I, Applerot G, Perkas N, et al. Antibacterial properties of an in situ generated and simultaneously deposited nanocrystalline ZnO on fabrics. ACS Appl Mater Interfaces 2009; 1: 361-366.
7. Choi HS, Frangioni JV. Nanoparticles for biomedical imaging: fundamentals of clinical translation. Mol Imaging 2010; 9: 291-310.
8. Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater 2005; 4: 435-446.
9. Kim BY, Rutka JT, Chan WC. Nanomedicine. N Engl J Med 2010; 363: 2434-2443.
10. Reimer P, Balzer T. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol 2003; 13: 1266-1276.
11. Elias A, Tsourkas A. Imaging circulating cells and lymphoid tissues with iron oxide nanoparticles. Hematology Am Soc Hematol Educ Program 2009: 720-726.
12. Fahlvik AK, Klaveness J, Stark DD. Iron oxides as MR imaging contrast agents. J Magn Reson Imaging 1993; 3: 187-194.
13. Islam T, Josephson L. Current state and future applications of active targeting in malignancies using superparamagnetic iron oxide nanoparticles. Cancer Biomark 2009; 5: 99-107.
14. Rivera Gil P, Huhn D, del Mercato LL, Sasse D, Parak WJ. Nanopharmacy: Inorganic nanoscale devices as vectors and active compounds. Pharmacol Res 2010; 62: 115-25.
15. Naqvi S, Samim M, Abdin M, et al. Concentration-dependent toxicity of iron oxide nanoparticles mediated by increased oxidative stress. Int J Nanomedicine 2010; 5: 983-989.
16. Plum LM, Rink L, Haase H. The essential toxin: impact of zinc on human health. Int J Environ Res Public Health 2010; 7: 1342-1365.
17. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348: 2491-2499.
18. Schulze E, Ferrucci JT, Jr., Poss K, Lapointe L, Bogdanova A, Weissleder R. Cellular uptake and trafficking of a prototypical magnetic iron oxide label in vitro. Invest Radiol 1995; 30: 604-610.
19. Ferrucci JT, Stark DD. Iron oxide-enhanced MR imaging of the liver and spleen: review of the first 5 years. AJR Am J Roentgenol 1990; 155: 943-950.
20. Perazella MA. Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. Curr Drug Saf 2008; 3: 67-75.
21. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation 2010; 121: e46-e215.
22. Whelan RS, Kaplinskiy V, Kitsis RN. Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu Rev Physiol 2010; 72: 19-44.
23. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 1994; 94: 1621-1628.
24. Kang PM, Haunstetter A, Aoki H, Usheva A, Izumo S. Morphological and molecular characterization of adult cardiomyocyte apoptosis during hypoxia and reoxygenation. Circ Res 2000; 87: 118-125.
25. Chiu JJ, Chien S. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev 2011; 91: 327-387.
26. Slevin M, Badimon L, Grau-Olivares M, et al. Combining nanotechnology with current biomedical knowledge for the vascular imaging and treatment of atherosclerosis. Mol Biosyst 2010; 6: 444-450.
27. Young VEL, Yang TY, Sadat U, Gillard JH. Molecular MRI of Atherosclerosis. Curr Cardiovasc Imaging Rep 2010; 4: 4-11.
28. Tang TY, Howarth SP, Miller SR, et al. Comparison of the inflammatory burden of truly asymptomatic carotid atheroma with atherosclerotic plaques contralateral to symptomatic carotid stenosis: an ultra small superparamagnetic iron oxide enhanced magnetic resonance study. J Neurol Neurosurg Psychiatry 2007; 78: 1337-1343.
29. Silvera SS, Aidi HE, Rudd JH, et al. Multimodality imaging of atherosclerotic plaque activity and composition using FDGPET/CT and MRI in carotid and femoral arteries. Atherosclerosis 2009; 207: 139-143.
30. Hucker WJ, Jaffer FA. F-FDG PET Imaging of Atherosclerosis-A New Approach to Detect Inflamed, High-Risk Coronary Plaques? Curr Cardiovasc Imaging Rep 2011; 4: 1-3.
31. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 1997; 28: 2109-2118.
32. Bi F, Zhang J, Su Y, Tang YC, Liu JN. Chemical conjugation of urokinase to magnetic nanoparticles for targeted thrombolysis. Biomaterials 2009; 30: 5125-5130.
33. Ma YH, Wu SY, Wu T, Chang YJ, Hua MY, Chen JP. Magnetically targeted thrombolysis with recombinant tissue plasminogen activator bound to polyacrylic acid-coated nanoparticles. Biomaterials 2009; 30: 3343-3351.
34. Marder VJ, Chute DJ, Starkman S, et al. Analysis of thrombi retrieved from cerebral arteries of patients with acute ischemic stroke. Stroke 2006; 37: 2086-2093.
35. Botnar RM, Perez AS, Witte S, et al. In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent. Circulation 2004; 109: 2023-9.
36. Flacke S, Fischer S, Scott MJ, et al. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 2001; 104: 1280-1285.
37. Winter PM, Caruthers SD, Yu X, et al. Improved molecular imaging contrast agent for detection of human thrombus. Magn Reson Med 2003; 50: 411-416.
38. Morawski AM, Winter PM, Yu X, et al. Quantitative "magnetic resonance immunohistochemistry" with ligand-targeted (19)Fnanoparticles. Magn Reson Med 2004; 52: 1255-1262.
39. Vymazal J, Spuentrup E, Cardenas-Molina G, et al. Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: results of a phase II clinical study of feasibility. Invest Radiol 2009; 44: 697-704.
40. Spuentrup E, Botnar RM, Wiethoff AJ, et al. MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients. Eur Radiol 2008; 18: 1995-2005.
41. Tung CH, Gerszten RE, Jaffer FA, Weissleder R. A novel nearinfrared fluorescence sensor for detection of thrombin activation in blood. Chembiochem 2002; 3: 207-11.
42. Jaffer FA, Tung CH, Wykrzykowska JJ, et al. Molecular imaging of factor XIIIa activity in thrombosis using a novel, near-infrared fluorescent contrast agent that covalently links to thrombi. Circulation 2004; 110: 170-176.
43. Tung CH, Quinti L, Jaffer FA, Weissleder R. A branched fluorescent peptide probe for imaging of activated platelets. Mol Pharm 2005; 2: 92-95.
44. Bates SM, Lister-James J, Julian JA, Taillefer R, Moyer BR, Ginsberg JS. Imaging characteristics of a novel technetium Tc 99mlabeled platelet glycoprotein IIb/IIIa receptor antagonist in patients With acute deep vein thrombosis or a history of deep vein thrombosis. Arch Intern Med 2003; 163: 452-456.
45. Totani L, Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol 2010; 30: 2357-2361.
46. Chaubet F, Bertholon I, Serfaty JM, et al. A new macromolecular paramagnetic MR contrast agent binds to activated human platelets. Contrast Media Mol Imaging 2007; 2: 178-188.
47. Young VEL, Tang TY, Sadat U, Gillard JH. Molecular MRI of atherosclerosis. Curr Cardiovasc Imaging Rep 2010; 3: 4-11.
48. von zur Muhlen C, von Elverfeldt D, Moeller JA, et al. Magnetic resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis. Circulation 2008; 118: 258-267.
49. Kang PM, Izumo S. Apoptosis in heart: basic mechanisms and implications in cardiovascular diseases. Trends Mol Med 2003; 9: 177-182.
50. van Tilborg GA, Mulder WJ, Chin PT, et al. Annexin A5- conjugated quantum dots with a paramagnetic lipidic coating for the multimodal detection of apoptotic cells. Bioconjug Chem 2006; 17: 865-868.
51. Smith BR, Heverhagen J, Knopp M, et al. Localization to atherosclerotic plaque and biodistribution of biochemically derivatized superparamagnetic iron oxide nanoparticles (SPIONs) contrast particles for magnetic resonance imaging (MRI). Biomed Microdevices 2007; 9: 719-727.
52. Burtea C, Laurent S, Lancelot E, et al. Peptidic targeting of phosphatidylserine for the MRI detection of apoptosis in atherosclerotic plaques. Mol Pharm 2009; 6: 1903-1919.
53. Maiseyeu A, Mihai G, Kampfrath T, et al. Gadolinium-containing phosphatidylserine liposomes for molecular imaging of atherosclerosis. J Lipid Res 2009; 50: 2157-2163.
54. Cook NR, Albert CM, Gaziano JM, et al. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. Arch Intern Med 2007; 167: 1610-1618.
55. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003; 361: 2017-2023.
56. Lee D, Erigala VR, Dasari M, Yu J, Dickson RM, Murthy N. Detection of hydrogen peroxide with chemiluminescent micelles. Int J Nanomedicine 2008; 3: 471-476.
57. Lee D, Khaja S, Velasquez-Castano JC, et al. In vivo imaging of hydrogen peroxide with chemiluminescent nanoparticles. Nat Mater 2007; 6: 765-769.
58. Kim S, Park H, Song Y, et al. Reduction of oxidative stress by phydroxybenzyl alcohol-containing biodegradable polyoxalate nanoparticulate antioxidant. Biomaterials 2011; 32: 3021-3029.
59. Kundu K, Knight SF, Willett N, Lee S, Taylor WR, Murthy N. Hydrocyanines: a class of fluorescent sensors that can image reactive oxygen species in cell culture, tissue, and in vivo. Angew Chem Int Ed Engl 2009; 48: 299-303.
60. Lim CK, Lee YD, Na J, et al. Chemiluminescence-Generating Nanoreactor Formulation for Near-Infrared Imaging of Hydrogen Peroxide and Glucose Level in vivo. Adv Funct Mater 2010; 20: 2644-2648.
61. Anderson SA, Rader RK, Westlin WF, et al. Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. Magn Reson Med 2000; 44: 433-439.
62. Cyrus T, Abendschein DR, Caruthers SD, et al. MR threedimensional molecular imaging of intramural biomarkers with targeted nanoparticles. J Cardiovasc Magn Reson 2006; 8: 535-541.
63. Lanza GM, Winter PM, Caruthers SD, et al. Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions. Angiogenesis 2010; 13: 189-202.
64. Lanza GM, Winter PM, Caruthers SD, et al. Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles. Nanomedicine (Lond) 2006; 1: 321-329.
65. Chen W, Vucic E, Leupold E, et al. Incorporation of an apoEderived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol Imaging 2008; 3: 233-242.
66. Frias JC, Williams KJ, Fisher EA, Fayad ZA. Recombinant HDLlike nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc 2004; 126: 16316-16317.
67. Cormode DP, Chandrasekar R, Delshad A, et al. Comparison of synthetic high density lipoprotein (HDL) contrast agents for MR imaging of atherosclerosis. Bioconjug Chem 2009; 20: 937-943.
68. Li H, Gray BD, Corbin I, et al. MR and fluorescent imaging of low-density lipoprotein receptors. Acad Radiol 2004; 11: 1251-1259.
69. McAteer MA, Akhtar AM, von Zur Muhlen C, Choudhury RP. An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using microparticles of iron oxide. Atherosclerosis 2010; 209: 18-27.
70. Nahrendorf M, Jaffer FA, Kelly KA, et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 2006; 114: 1504-1511.
71. Tsourkas A, Shinde-Patil VR, Kelly KA, et al. In vivo imaging of activated endothelium using an anti-VCAM-1 magnetooptical probe. Bioconjug Chem 2005; 16: 576-581.
72. Radermacher KA, Beghein N, Boutry S, et al. In vivo detection of inflammation using pegylated iron oxide particles targeted at Eselectin: a multimodal approach using MR imaging and EPR spectroscopy. Invest Radiol 2009; 44: 398-404.
73. Taillefer R. Radiolabeled peptides in the detection of deep venous thrombosis. Semin Nucl Med 2001; 31: 102-123.
74. Gustafsson B, Youens S, Louie AY. Development of contrast agents targeted to macrophage scavenger receptors for MRI of vascular inflammation. Bioconjug Chem 2006; 17: 538-547.
75. Lipinski MJ, Frias JC, Amirbekian V, et al. Macrophage-specific lipid-based nanoparticles improve cardiac magnetic resonance de tection and characterization of human atherosclerosis. JACC Cardiovasc Imaging 2009; 2: 637-647.
76. Mulder WJ, Strijkers GJ, Briley-Saboe KC, et al. Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEGmicelles. Magn Reson Med 2007; 58: 1164-1170.
77. Ronald JA, Chen JW, Chen Y, et al. Enzyme-sensitive magnetic resonance imaging targeting myeloperoxidase identifies active inflammation in experimental rabbit atherosclerotic plaques. Circulation 2009; 120: 592-599.
78. Nahrendorf M, Zhang H, Hembrador S, et al. Nanoparticle PETCT imaging of macrophages in inflammatory atherosclerosis. Circulation 2008; 117: 379-387.
79. Miller YI, Choi SH, Wiesner P, et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res 2011; 108: 235-248.
80. Briley-Saebo KC, Cho YS, Tsimikas S. Imaging of Oxidation- Specific Epitopes in Atherosclerosis and Macrophage-Rich Vulnerable Plaques. Curr Cardiovasc Imaging Rep 2011; 4: 4-16.
81. Briley-Saebo KC, Shaw PX, Mulder WJ, et al. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation 2008; 117: 3206-3215.
82. Briley-Saebo KC, Cho YS, Shaw PX, et al. Targeted iron oxide particles for in vivo magnetic resonance detection of atherosclerotic lesions with antibodies directed to oxidation-specific epitopes. J Am Coll Cardiol 2010; 57: 337-347.
83. Hauck TS, Anderson RE, Fischer HC, Newbigging S, Chan WC. In vivo quantum-dot toxicity assessment. Small 2010; 6: 138-144.
84. Schipper ML, Nakayama-Ratchford N, Davis CR, et al. A pilot toxicology study of single-walled carbon nanotubes in a small sample of mice. Nat Nanotechnol 2008; 3: 216-221.
85. Derfus AM, Chan WCW, Bhatia SN. Probing the cytotoxicity of semiconductor quantum dots. Nano Lett 2004; 4: 11-18.
86. Poland CA, Duffin R, Kinloch I, et al. Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat Nanotechnol 2008; 3: 423-428.
87. Johannsen M, Gneveckow U, Taymoorian K, et al. Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective phase I trial. Int J Hyperthermia 2007; 23: 315-323.